Trial Details

Not Recruiting
Basic Information
Clinical ID c5413
Identifier ACTRN12624001448538
Trial Title Concentrations of Thioguanine and its metabolite 6-TGN in Blood and Colon Tissue Samples and the Drug Effect in Active Ulcerative Colitis Patients Administered Extended-release Thioguanine tablets
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Inflammatory Bowel Disease;Active Ulcerative Colitis; Inflammatory Bowel Disease Active Ulcerative Colitis;Oral and Gastrointestinal - Inflammatory bowel disease
Interventions Administration of thioguanine by extended-release oral tablets once daily, Cohort 1 has 6 participants who will receive 20mg for 14 weeks. If there is evidence of efficacy and no significant toxicity after 14 weeks of thioguanine administration in cohort
Participant Information
Sponsor Douglas Pharmaceuticals
City NULL
Country/Region New Zealand
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, ELDER, OLDER_ADULT
Study Design
Study Type Interventional
Phase PHASE1
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL